In order to promote the safe development of tumor CAR-T immunotherapy, effectively monitor the cytokine storm and neurotoxicity caused by tumor car-T immunotherapy, and reduce the risk of treatment, the company has developed two 7-item combined detection kits targeting IL-2\IL-4\IL-6\IL-10\IL-17\TNF \IFN-, and successfully obtained the registration certificate on May 14, 2020.